Retatrutide Protocol
Triple GIP/GLP-1/glucagon receptor agonist studied in human clinical trials for metabolic and weight research.
- Standard dose
- 5 mg
- Frequency
- 1× weekly, subcutaneous
- Route
- subcutaneous
- Cycle
- 12–24 weeks
- Vial
- 5 mg
Evidence Level: Emerging Evidence
Human and/or animal research exists and is accumulating, but the evidence base is not yet as extensive as an approved medicine.
Human evidence: Multiple completed Phase 2 trials and ongoing Phase 3 programs with published body-weight and metabolic-marker outcomes.
Animal evidence: Preceded by rodent and non-human primate metabolic studies establishing the tri-agonist mechanism.
Introduction & Mechanism of Action
Triple GIP/GLP-1/glucagon receptor agonist studied in human clinical trials for metabolic and weight research.
Long-acting unimolecular tri-agonist; glucagon-receptor activity is the key differentiator from dual GIP/GLP-1 agonists, adding energy-expenditure and hepatic-lipid effects on top of appetite suppression.
Receptors/targets: GIP receptor, GLP-1 receptor, Glucagon receptor
Areas of Research Interest
- Weight-management research
- Glucose regulation
- Cardiometabolic outcomes
Benefits Reported in Research
- Appetite and metabolic-rate research
- Cardiometabolic marker studies
- Body-composition research
Reported Research Dosing Range
The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.
Reported range: 2–8 mg
Reported frequency: 1× weekly, subcutaneous
Reported cycle duration: 12–24 weeks
Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.
Research Reference Data
Published research on Retatrutide reports administration at 2–8 mg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.
| Variant | Route | Reported frequency | Reported dose |
|---|---|---|---|
| Standard Protocol | subcutaneous | 1× weekly, subcutaneous | 5 mg |
Reconstitution Reference
Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.
Open the research calculator, pre-filled for Retatrutide →Research Protocol Timeline
A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.
- 01
Formulation
Supplied as a lyophilized 5 mg vial requiring reconstitution before research use.
- 02
Reconstitution Reference
Published research protocols reconstitute this vial with 2 mL bacteriostatic water to reach 2.50 mg/mL.
- 03
Reported Research Administration
Published research describes 1× weekly, subcutaneous administration via subcutaneous route, at 5 mg per administration.
- 04
Cycle Reference
Published protocols describe a cycle duration of 12–24 weeks. Consult a physician before beginning any new research cycle.
Dilution Guide
Reconstitute with 2 mL bacteriostatic water
Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.
Handling Guide
General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.
Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.
Storage
Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.
Monitoring
Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.
Side Effects
- Nausea
- Vomiting
- Diarrhea or constipation
- Injection-site reaction
- Decreased appetite
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Pregnancy
Drug interactions
- May alter absorption of oral medications due to delayed gastric emptying
- Insulin or sulfonylureas — increased hypoglycemia risk when combined
Safety
- Gastrointestinal intolerance during titration
- Theoretical thyroid C-cell risk flagged for the GLP-1 receptor agonist class
- Gallbladder-related events reported in trial data for the class
Not yet a generally authorized medicine. Benefits and risks must be interpreted by indication and trial phase.
Expected Results & Comparison
In published trial data, Retatrutide has shown numerically greater mean body-weight reduction than tirzepatide or semaglutide, largely attributed to its added glucagon-receptor agonism. No head-to-head trial against tirzepatide has been published, so "stronger" reflects separate-trial comparisons, not a direct comparison.